---
pmid: '18026102'
title: Cystatin C modulates cerebral beta-amyloidosis.
authors:
- Kaeser SA
- Herzig MC
- Coomaraswamy J
- Kilger E
- Selenica ML
- Winkler DT
- Staufenbiel M
- Levy E
- Grubb A
- Jucker M
journal: Nat Genet
year: '2007'
full_text_available: false
doi: 10.1038/ng.2007.23
---

# Cystatin C modulates cerebral beta-amyloidosis.
**Authors:** Kaeser SA, Herzig MC, Coomaraswamy J, Kilger E, Selenica ML, Winkler DT, Staufenbiel M, Levy E, Grubb A, Jucker M
**Journal:** Nat Genet (2007)
**DOI:** [10.1038/ng.2007.23](https://doi.org/10.1038/ng.2007.23)

## Abstract

1. Nat Genet. 2007 Dec;39(12):1437-9. doi: 10.1038/ng.2007.23. Epub 2007 Nov 18.

Cystatin C modulates cerebral beta-amyloidosis.

Kaeser SA(1), Herzig MC, Coomaraswamy J, Kilger E, Selenica ML, Winkler DT, 
Staufenbiel M, Levy E, Grubb A, Jucker M.

Author information:
(1)Department of Cellular Neurology, Hertie-Institute for Clinical Brain 
Research, University of Tübingen, Otfried-Müller Strasse 27, D-72076 Tübingen, 
Germany.

The CST3 Thr25 allele of CST3, which encodes cystatin C, leads to reduced 
cystatin C secretion and conveys susceptibility to Alzheimer's disease. Here we 
show that overexpression of human cystatin C in brains of APP-transgenic mice 
reduces cerebral amyloid-beta deposition and that cystatin C binds amyloid-beta 
and inhibits its fibril formation. Our results suggest that cystatin C 
concentrations modulate cerebral amyloidosis risk and provide an opportunity for 
genetic risk assessment and therapeutic interventions.

DOI: 10.1038/ng.2007.23
PMID: 18026102 [Indexed for MEDLINE]
